KISQALI vs SUTENT

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Possible drug interaction. KISQALI and SUTENT are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	KISQALI	SUTENT
Rating	70/100	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	RIBOCICLIB SUCCINATE	SUNITINIB MALATE
Manufacturer	Novartis	Cppi Cv
Dosage forms	Tablet	Capsule
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	Boxed warning
Treats	Breast Neoplasms	Renal Cell Carcinoma, Pancreatic Neoplasms, Neuroendocrine Tumors

kisqali sutent

Rating

70/100

New

Pharmacy pays

—

Type

Active ingredient

RIBOCICLIB SUCCINATE

SUNITINIB MALATE

Manufacturer

Novartis

Cppi Cv

Dosage forms

Tablet

Capsule

Drug class

Kinase Inhibitor

Boxed warning

None

Boxed warning

Treats

Breast Neoplasms

Renal Cell Carcinoma, Pancreatic Neoplasms, Neuroendocrine Tumors

Frequently asked questions

What is the difference between Kisqali and Sutent?

Kisqali contains Ribociclib Succinate, while Sutent contains Sunitinib Malate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.